It has been clearly reported that FOSL1 can also promote the progression of pancreatic cancer (Vallejo et al., 2017; Luo, He & Qiu, 2018), bile duct cancer (Vallejo et al., 2021), breast cancer (Kim et al., 2020; Chen et al., 2018), bladder cancer (Cui et al., 2020; Gatta et al., 2019), stomach cancer (He et al., 2015) and esophageal cancer (Shen et al., 2020) through direct or indirect mechanisms. Here, FOSL1 is linked to familial pancreatic carcinoma.